APUS director reports Form 4 option grant: 3,000 at $1.92

Rhea-AI Filing Summary

Apimeds Pharmaceuticals US, Inc. (APUS) director reported receiving a stock option grant. The option covers 3,000 shares of common stock at an exercise price of $1.92 per share, granted on 10/15/2025 and expiring on 10/15/2035.

The award vests in quarterly installments beginning October 1, 2025 and becomes fully vested after three years, subject to continued service. It is not exercisable until stockholder approval is obtained to amend the incentive plan to increase available shares. The option vests in full upon a Change in Control as defined in the plan.

Following the transaction, the reporting person beneficially owns 3,000 derivative securities on a direct basis.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kogan Elona

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	3,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 3,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kogan Elona

(Last) (First) (Middle)

C/O APIMEDS PHARMACEUTICALS US, INC.

100 MATAWAN ROAD, SUITE 325

(Street)

MATAWAN NJ 07747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apimeds Pharmaceuticals US, Inc. [ APUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.92	10/15/2025		A		3,000		(1)	10/15/2035	Common Stock, par value $0.01 per share	3,000	$0	3,000	D

Explanation of Responses:

1. The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact	10/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did APUS report on Form 4?

A director received a stock option for 3,000 shares at an exercise price of $1.92 per share, granted on 10/15/2025.

When do the APUS options vest and expire?

They vest quarterly starting October 1, 2025 and are fully vested after three years. The options expire on 10/15/2035.

Are the APUS options immediately exercisable?

No. They are not exercisable until stockholder approval is obtained to amend the incentive plan to increase available shares.

How many options does the director hold after the transaction?

The director beneficially owns 3,000 derivative securities following the reported transaction, held directly.

Is there accelerated vesting for these APUS options?

Yes. The options vest in full upon a Change in Control as defined in the plan.

What is the exercise price of the APUS stock option grant?

The exercise price is $1.92 per share.